ZDHHC2

Across TCGA pan-cancer cohorts, ZDHHC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZDHHC2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ZDHHC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZDHHC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where ZDHHC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	1.000	0.873	.004	12	view →
PDAC	OS	Median	All	0.956	0.520	.012	9	view →
UCEC	OS	Tertile	All	1.000	0.606	.043	4	view →
LUAD	OS	Median	All	0.924	0.633	.040	4	view →
GBM	OS	Tertile	All	0.881	0.700	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZDHHC2–LSCC (DFS)

Open the LSCC breakdown →